Article

Discussing Cancer Symptom Management With Nurse Darcy Burbage

Author(s):

Cancer survivors often experience physical and psychosocial long-term and late effects after treatment ends.

Cancer survivors often experience physical and psychosocial long-term and late effects after treatment ends. Although most individuals experience some types of side effects during treatment, it is often surprising to survivors that some side effects can linger on after treatment is over, or can appear later on.

Nurses and patients have a lot to learn from each other to help us better understand and manage the effects of cancer treatment.

Please join our guest host Darcy Burbage (@DarcyBurbage on Twitter) as we discuss the challenges of treatment-related changes and share resources and advice.

Darcy is a survivorship nurse navigator and oncology nurse advocate, focused on bringing evidence- based strategies for quality survivorship care to oncology. Darcy guest blogs for Oncology Nursing News and also has written for the Association of Community Cancer Centers. She is a highly regarded nurse leader, currently serving as Chair of the ONS Communities Advisory Panel with the Oncology Nursing Society.

We hope to see you Thursday, July 7th on Twitter at 9 p.m. EST. Don’t forget to include the #CureConnect hashtag in all of your responses! Read more here about the #CureConnect chat and how to participate.

Tweet: I’ll be at the #CureConnect chat July 7 at 9pm EST with @cure_magazine and @oncnursingnews talking symptom management. Join me!

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Related Content